Interview with Thierry Poiraud, General Manager, Menarini France
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
Address: Menarini Building 1 rue du Jura 94633 Rungis Cedex BP 40528, France
Tel: 01 45 60 77 20
Web: http://www.menarini.fr/accueil/
Menarini started up its operations in Feb 1992 with a product portfolio acquired through an exchange of products with Sanofi. From this base, the affiliate ventured onto the French market and in 1993 it launched an original gel with analgesic and anti-inflammatory properties, and in a few months time it became the leader in this therapeutic class. Three innovative cardiovascular products have been launched successively in 2002 and 2004.
MENARINI, 1 Italian pharmaceutical group, today operates in over 100 countries. With over 2.6 billion euros in turnover, 12 500 employees, the Menarini Group is the 20th in European rankings and 36th in the world rankings.
France: 112.5 million euros in 2008; employs 600 (heavy growth in last 5 years, double # last 3 years and wants 150m euro for 2010)
Distribution of turnover: 30% Self-Medication – Ethical Drugs 70%
Commercial/Mkting autonomy for HQ
2 launches in 2009: cardiology, angina pectoris
Sports medicine and Rhumatology in France
Present in the most important therapeutic areas of greatest importance, including:
• Cardiovascular Products
• Gastro-intestinal Products
• Antibiotics / Respiratory System Products
• Diabetes
• Anti-inflammatory agents / Analgesics
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how Ipsen has managed to achieve sales growth in 2020 despite the pandemic, diagnostics…
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s new Chinese acquisition catapults it into the world’s top 5 CDMOs, Ipsen’s resilient…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on…
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new products in the midst of a global pandemic…
French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679 million in vaccine manufacturing operations in the next two…
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed CEO of fellow French firm Ipsen on the 28th May 2020, effective 1st July. Loew,…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
Speaking exclusively to PharmaBoardroom at the International Women’s Day 2020 event at the Franco-British Chamber of Commerce in Paris, esteemed cardiologist Professor Claire Mounier-Vehier outlines why cardiovascular disease is not…
Researchers at the Institut Pasteur in Paris have become the first in Europe to fully sequence the genome of the 2019-nCoV coronavirus – putting the Institut at the forefront of…
See our Cookie Privacy Policy Here